Regenerex Pharma (RGPX) Debt to Equity (2017 - 2024)
Regenerex Pharma (RGPX) reported Debt to Equity of -$0.05 for Q1 2024, up 61.38% year-over-year from -$0.03 in Q2 2023, and down 6178.8% quarter-over-quarter from -$0.0 in Q4 2023.
Regenerex Pharma (RGPX) Debt to Equity (2017 - 2024) Analysis & Trends
Regenerex Pharma (RGPX) has 8 years of Debt to Equity data on file, last reported at -$0.05 in Q1 2024.
- Debt to Equity for Q1 2024 came in at -$0.05, up 61.38% year-over-year; the trailing twelve-month figure through Mar 2024 was -$0.05 (up 61.38% YoY), and the FY2024 annual result was -$0.05, up 61.38% from the prior year.
- Debt to Equity retreated to -$0.05 in Q1 2024 per RGPX's latest filing, from -$0.0 in the prior quarter.
- Over five years, Debt to Equity peaked at -$0.0 in Q4 2021 and troughed at -$0.27 in Q1 2020.
- A 5-year average of -$0.13 and a median of -$0.13 in 2022 frame the typical range for Debt to Equity.
- The sharpest annual moves came in 2022 and 2023: Debt to Equity slumped 114700.05% in 2022, then soared 99.43% in 2023.
- A 5-year view of Debt to Equity shows it stood at -$0.25 in 2020, then soared by 99.96% to -$0.0 in 2021, then tumbled by 114700.05% to -$0.12 in 2022, then surged by 99.41% to -$0.0 in 2023, then slumped by 6178.8% to -$0.05 in 2024.
- Business Quant data shows RGPX's Debt to Equity at -$0.05 in Q1 2024, -$0.0 in Q4 2023, and -$0.0 in Q3 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -0.05 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | -0.12 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -0.13 |
| Mar 31, 2022 | -0.13 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | -0.15 |
| Jun 30, 2021 | -0.15 |
| Mar 21, 2021 | -0.16 |
| Sep 30, 2020 | -0.25 |
| Jun 30, 2020 | -0.27 |
| Mar 31, 2020 | -0.27 |
| Dec 31, 2019 | -0.30 |
| Sep 30, 2019 | -0.31 |
| Jun 30, 2019 | -0.33 |
| Mar 31, 2019 | -0.35 |
| Dec 31, 2018 | -0.15 |